MORGANTOWN, W.Va., April 30, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today it has begun a collaborative research initiative with the Memorial Sloan-Kettering Cancer Center (MSK) and the Dana-Farber Cancer Institute (Dana-Farber) that uses Protea’s next generation LAESI direct molecular imaging technology to analyze cancer cells. The initial focus is early stage lung adenocarcinoma.
Help employers find you! Check out all the jobs and post your resume.
